 | |
| Clinical data | |
|---|---|
| AHFS/Drugs.com | International Drug Names |
| Routes of administration | Oral |
| ATC code | |
| Identifiers | |
| |
| CAS Number | |
| PubChemCID | |
| ChemSpider |
|
| UNII | |
| KEGG |
|
| CompTox Dashboard(EPA) | |
| ECHA InfoCard | 100.118.935 |
| Chemical and physical data | |
| Formula | C22H29N3O4S |
| Molar mass | 431.55 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
 N Y (what is this?) (verify) | |
Lafutidine (INN) is a second generationhistamine H2 receptor antagonist having multimodal mechanism of action and used to treatgastrointestinal disorders.[1] It is marketed in South Korea, Japan and India.
Lafutidine is used to treatgastric ulcers,duodenal ulcers, as well as wounds in the lining of the stomach associated with acutegastritis and acute exacerbation of chronic gastritis.[2][3]
Adverse events observed during clinical trials includedconstipation,diarrhea, drugrash,nausea,vomiting anddizziness.[3]
Like otherH2 receptor antagonists, lafutidineacts by preventing the secretion ofgastric acid.[3] It also activatescalcitonin gene-related peptide, resulting in the stimulation ofnitric oxide (NO) and regulation of gastric mucosal blood flow, increasessomatostatin levels also resulting in less gastric acid secretion, causes the stomach lining to generate moremucin, inhibitsneutrophil activation thus preventing injury frominflammation, and blocks the attachment ofHelicobacter pylori to gastric cells.[3]
It is marketed in Japan asStogar byUCB[2] and in India asLafaxid by Zuventus Healthcare.[3] It is also marketed in South Korea asIldong Lafutidine by Ildong Pharmaceutical Co Ltd.